vs
QuidelOrtho Corp（QDEL）与Sunrun Inc.（RUN）财务数据对比。点击上方公司名可切换其他公司
Sunrun Inc.的季度营收约是QuidelOrtho Corp的1.7倍（$1.2B vs $699.9M），Sunrun Inc.净利率更高（8.9% vs -104.7%，领先113.7%），Sunrun Inc.同比增速更快（123.5% vs -3.7%），过去两年Sunrun Inc.的营收复合增速更高（59.0% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Sunrun Inc.是美国知名的光伏系统及电池储能产品供应商，业务以服务住宅客户为主，2007年成立，总部位于加利福尼亚州旧金山，致力于为家庭用户提供高效的清洁能源解决方案。
QDEL vs RUN — 直观对比
营收规模更大
RUN
是对方的1.7倍
$699.9M
营收增速更快
RUN
高出127.2%
-3.7%
净利率更高
RUN
高出113.7%
-104.7%
两年增速更快
RUN
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $1.2B |
| 净利润 | $-733.0M | $103.6M |
| 毛利率 | — | — |
| 营业利润率 | -100.7% | 8.4% |
| 净利率 | -104.7% | 8.9% |
| 营收同比 | -3.7% | 123.5% |
| 净利润同比 | -3583.4% | 103.7% |
| 每股收益（稀释后） | $-10.78 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRUN
| Q4 25 | — | $1.2B | ||
| Q3 25 | $699.9M | $724.6M | ||
| Q2 25 | $613.9M | $569.3M | ||
| Q1 25 | $692.8M | $504.3M | ||
| Q4 24 | $707.8M | $518.5M | ||
| Q3 24 | $727.1M | $537.2M | ||
| Q2 24 | $637.0M | $523.9M | ||
| Q1 24 | $711.0M | $458.2M |
净利润QDELRUN
| Q4 25 | — | $103.6M | ||
| Q3 25 | $-733.0M | $16.6M | ||
| Q2 25 | $-255.4M | $279.8M | ||
| Q1 25 | $-12.7M | $50.0M | ||
| Q4 24 | $-178.4M | $-2.8B | ||
| Q3 24 | $-19.9M | $-83.8M | ||
| Q2 24 | $-147.7M | $139.1M | ||
| Q1 24 | $-1.7B | $-87.8M |
营业利润率QDELRUN
| Q4 25 | — | 8.4% | ||
| Q3 25 | -100.7% | 0.5% | ||
| Q2 25 | -29.4% | -19.7% | ||
| Q1 25 | 4.7% | -22.8% | ||
| Q4 24 | -14.2% | -628.0% | ||
| Q3 24 | 2.1% | -23.8% | ||
| Q2 24 | -18.4% | -24.4% | ||
| Q1 24 | -247.3% | -40.0% |
净利率QDELRUN
| Q4 25 | — | 8.9% | ||
| Q3 25 | -104.7% | 2.3% | ||
| Q2 25 | -41.6% | 49.1% | ||
| Q1 25 | -1.8% | 9.9% | ||
| Q4 24 | -25.2% | -542.7% | ||
| Q3 24 | -2.7% | -15.6% | ||
| Q2 24 | -23.2% | 26.5% | ||
| Q1 24 | -239.9% | -19.2% |
每股收益（稀释后）QDELRUN
| Q4 25 | — | $0.38 | ||
| Q3 25 | $-10.78 | $0.06 | ||
| Q2 25 | $-3.77 | $1.07 | ||
| Q1 25 | $-0.19 | $0.20 | ||
| Q4 24 | $-2.54 | $-12.59 | ||
| Q3 24 | $-0.30 | $-0.37 | ||
| Q2 24 | $-2.20 | $0.55 | ||
| Q1 24 | $-25.50 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | — |
| 总债务越低越好 | $2.5B | $14.7B |
| 股东权益账面价值 | $2.0B | $3.1B |
| 总资产 | $5.7B | $22.6B |
| 负债/权益比越低杠杆越低 | 1.23× | 4.69× |
8季度趋势，按日历期对齐
现金及短期投资QDELRUN
| Q4 25 | — | — | ||
| Q3 25 | $98.1M | — | ||
| Q2 25 | $151.7M | — | ||
| Q1 25 | $127.1M | — | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | — | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $78.5M | — |
总债务QDELRUN
| Q4 25 | — | $14.7B | ||
| Q3 25 | $2.5B | $14.6B | ||
| Q2 25 | $2.1B | $14.0B | ||
| Q1 25 | $2.1B | $13.6B | ||
| Q4 24 | $2.1B | $12.9B | ||
| Q3 24 | $2.2B | $12.5B | ||
| Q2 24 | $2.2B | $12.0B | ||
| Q1 24 | $2.2B | $11.1B |
股东权益QDELRUN
| Q4 25 | — | $3.1B | ||
| Q3 25 | $2.0B | $3.0B | ||
| Q2 25 | $2.8B | $2.9B | ||
| Q1 25 | $3.0B | $2.6B | ||
| Q4 24 | $3.0B | $2.6B | ||
| Q3 24 | $3.2B | $5.3B | ||
| Q2 24 | $3.2B | $5.4B | ||
| Q1 24 | $3.3B | $5.2B |
总资产QDELRUN
| Q4 25 | — | $22.6B | ||
| Q3 25 | $5.7B | $22.2B | ||
| Q2 25 | $6.4B | $21.2B | ||
| Q1 25 | $6.5B | $20.4B | ||
| Q4 24 | $6.4B | $19.9B | ||
| Q3 24 | $6.8B | $22.1B | ||
| Q2 24 | $6.7B | $21.4B | ||
| Q1 24 | $6.7B | $20.8B |
负债/权益比QDELRUN
| Q4 25 | — | 4.69× | ||
| Q3 25 | 1.23× | 4.90× | ||
| Q2 25 | 0.74× | 4.80× | ||
| Q1 25 | 0.70× | 5.19× | ||
| Q4 24 | 0.72× | 5.05× | ||
| Q3 24 | 0.68× | 2.36× | ||
| Q2 24 | 0.70× | 2.23× | ||
| Q1 24 | 0.68× | 2.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $96.9M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | — |
| 自由现金流率自由现金流/营收 | -13.5% | — |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.94× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | — |
8季度趋势，按日历期对齐
经营现金流QDELRUN
| Q4 25 | — | $96.9M | ||
| Q3 25 | $-45.5M | $-121.5M | ||
| Q2 25 | $-46.8M | $-292.7M | ||
| Q1 25 | $65.6M | $-104.2M | ||
| Q4 24 | $63.7M | $-258.4M | ||
| Q3 24 | $117.9M | $-156.2M | ||
| Q2 24 | $-97.9M | $-208.5M | ||
| Q1 24 | $-700.0K | $-143.1M |
自由现金流QDELRUN
| Q4 25 | — | — | ||
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | $-156.4M | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — |
自由现金流率QDELRUN
| Q4 25 | — | — | ||
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | -29.1% | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — |
资本支出强度QDELRUN
| Q4 25 | — | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | 0.0% | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — |
现金转化率QDELRUN
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | -7.33× | ||
| Q2 25 | — | -1.05× | ||
| Q1 25 | — | -2.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.50× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RUN
| Products | $692.3M | 60% |
| Customer Agreements | $435.2M | 38% |
| Manufactured Product Other | $56.7M | 5% |
| Incentives | $31.3M | 3% |
